Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX): 4 pipeline candidates · 4 upcoming catalysts · ~20 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
19.8 months
D/E 0.12 · 0% dilution
Lead: Phase 3
4 candidates
4 upcoming, next in ~287d
N/A
A transparent, data-derived signal for Celldex Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.6B
Cash
$35.7M
Quarterly Burn
$65.6M
Runway
19.8 mo
Revenue
$15K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| barzolvolimab | Phase 2 |
| Barzolvolimab (CDX-0159) | Phase 3 |
| CDX-622 | Phase 1 |
| Next generation bispecific antibody platform | — |
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$2.03B
| Holder | Shares | Value |
|---|---|---|
| wellington management group llp | 8,560,476 | $271.5M |
| vanguard capital management llc | 5,921,790 | $187.8M |
| blackrock, inc. | 5,369,885 | $170.3M |
| fmr llc | 3,749,048 | $118.9M |
| state street corp | 2,804,168 | $88.9M |
| commodore capital lp | 2,696,616 | $85.5M |
| geode capital management, llc | 1,688,074 | $53.6M |
| braidwell lp | 1,356,082 | $43.0M |
| deep track capital, lp | 1,283,979 | $40.7M |
| millennium management llc | 1,253,532 | $39.8M |
Showing top 10 of 228 institutional holders of Celldex Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Celldex Therapeutics, Inc.'s pipeline?
Celldex Therapeutics, Inc. (CLDX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Celldex Therapeutics, Inc.'s lead drug candidate?
Celldex Therapeutics, Inc.'s most advanced tracked candidate is barzolvolimab (Phase 2) for Chronic Spontaneous Urticaria; Eosinophilic Esophagitis; Chronic Inducible Urticaria.
What is Celldex Therapeutics, Inc.'s next catalyst?
Celldex Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba" — expected April 1, 2027.
What is Celldex Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Celldex Therapeutics, Inc. has approximately 19.8 months of cash runway.
What is Celldex Therapeutics, Inc.'s market capitalization?
Celldex Therapeutics, Inc.'s market capitalization is approximately $2.6B.
Get the full picture on Celldex Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.